Lilly Advances Triple Agonist Retatrutide in Type 2 Diabetes Treatment

Eli Lilly and Company’s (Lilly) retatrutide, an investigational glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon triple hormone receptor agonist, has demonstrated statistically significant reductions in both glycated hemoglobin and body weight in a Phase III trial involving adults with type 2 diabetes, the company announced on March 19, 2026. The results position the therapy as a next-generation metabolic treatment candidate in an increasingly competitive GLP-1-based therapeutic landscape.¹

In the study, retatrutide achieved reductions in glycated hemoglobin of up to approximately 2.0% compared with placebo, alongside an average of 16.8% reduction in body weight over the treatment period.¹ These outcomes highlight the dual metabolic effects of the therapy, which is designed to target three hormonal pathways involved in glucose regulation and energy balance.

"For many people with type 2 diabetes, it is a struggle to achieve both A1C control and weight loss, since obesity has historically been harder to treat for those with type 2 diabetes," said Kenneth Custer, PhD, executive vice president and president, Lilly Cardiometabolic Health, in a company press release.¹ "With triple agonist retatrutide, we set out to make a molecule that could help patients achieve substantial A1C reduction and weight loss. These results support the remarkable potential of this novel molecule for people living with type 2 diabetes, with up to 2% A1C improvement and nearly 17% weight loss in 40 weeks of treatment."

How do Phase III results position retatrutide in the metabolic disease landscape?

As a triple agonist, retatrutide activates receptors for GLP-1, GIP, and glucagon, combining mechanisms associated with appetite suppression, glycemic control, and increased energy expenditure. The therapy is administered as a once-weekly injection and is being evaluated across multiple late-stage clinical programs in obesity and diabetes.

The Phase III findings extend prior clinical evidence demonstrating substantial metabolic effects with retatrutide. In the current study, patients receiving the therapy experienced greater reductions in both glycated hemoglobin and body weight compared with placebo, reinforcing the potential of multi-receptor agonism to address overlapping metabolic endpoints.

Across doses, patients achieved mean glycated hemoglobin reductions of approximately 1.7% to 2.0%, compared with 0.8% in the placebo group. Weight loss averaged up to roughly 15%, with higher-dose cohorts achieving greater reductions. These results suggest that retatrutide may offer differentiated efficacy relative to earlier-generation incretin-based therapies.^1,2

The findings are consistent with earlier studies of the molecule, including Phase II data demonstrating weight reductions exceeding 20% at extended treatment durations. In addition, prior Phase III data in obesity and osteoarthritis showed weight loss approaching 30% in some patient populations, alongside improvements in physical function and pain.^1,3

Taken together, the clinical dataset indicates that retatrutide may achieve both glycemic control and substantial weight reduction, two outcomes that are often difficult to optimize simultaneously in patients with type 2 diabetes, according to Lilly.

What differentiates triple agonists from existing incretin therapies?

Retatrutide’s mechanism distinguishes it from established therapies that primarily target one or two incretin pathways. By engaging glucagon receptor activity in addition to GLP-1 and GIP signaling, the therapy is designed to enhance energy expenditure while maintaining glycemic control.

This multi-receptor approach reflects a broader industry trend toward combination or multi-agonist therapies aimed at improving efficacy beyond that achievable with single-pathway modulation. Early data suggest that triple agonists may deliver greater weight loss than current standards of care, although tolerability profiles, including gastrointestinal adverse events, remain an area of ongoing evaluation.²

References

1. Eli Lilly and Company. Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes. Press Release. March 19, 2026.
2. Goldney J, Hamza M, Surti F, Davies MJ, Papamargaritis D. Triple Agonism Based Therapies for Obesity. Curr Cardiovasc Risk Rep. 2025;19(1):18. doi: 10.1007/s12170-025-00770-z
3. Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proc (Bayl Univ Med Cent). 2025;38(3):291-303. doi: 10.1080/08998280.2025.2456441